MedTrace Logo

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

NCT07684820 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-08-07

No results posted yet for this study

Summary

This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

EXPD-101/FXS7553 Dose 1

Oral tablet

DRUG

EXPD-101/FXS7553 Dose 2

Oral tablet

DRUG

Placebo

EXPD-101/FXS7553 - matching oral tablet.

Sponsors & Collaborators

  • Expedition Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • James Duncan Chalmers, MBChB, PhD · Radcliffe Department of Medicine, University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-06-30
Completion
2028-07-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07684820 on ClinicalTrials.gov